Previous 10 | Next 10 |
London, UK – 20 April 2022 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced it is partnering with One Mind, a leading mental health r...
Roth Capital Partners analyst Elemer Piros has issued an industry note covering six psychedelic drug companies. All have received buy ratings and Piros has assigned price targets for each stock. Cancer Therapy Similarities The main premise for the buy rating is the...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 13, 2022 – Anxiety disorders are the most common mental illness in the US, affecting approximately 40 million adults each year, and despite the abundance of antianxiety med...
Using huge amounts of money to invest in a business with no products seems like a fool’s errand. But in the psychedelics world, that’s just what’s going on. Big money from billionaires like Peter Thiel and others is pouring in because of big predictions ...
LONDON, April 04, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that members of its management team will present at the 21 st Annual Needh...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – March 30, 2022 – Depression and anxiety affect millions around the world and the venom of a toad is the latest psychedelic compound being used as an alternative treat...
COMPASS Pathways (NASDAQ:CMPS) trades 3.05% higher premarket after it formed a long-term strategic partnership to launch The Centre for Mental Health Research and Innovation for accelerating psychedelic research and develop new models of care for mental health in the U.K. It is...
Pioneering c ollaboration with King’s College London and South London and Maudsley NHS Foundation Trust London, UK, 24 March 2022 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health c...
The world may be a step closer to successfully treating obesity with psilocybin. That's because psilocybin activates serotonin receptors, or "nature's own appetite suppressant," as noted by Psychology Today. "This powerful brain chemical curbs cravings and shuts off appetite. It makes you f...
Psilocybin is the focus of more researchers and more business developers than ever before as study after study demonstrate its range of effectiveness. In fact, to date, over 27,000 scientific articles have been published on psychedelic drugs, with over 1,000 particular...
News, Short Squeeze, Breakout and More Instantly...
Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in fourth quarter 2024 Gino Santini to join Board of Directors as Chairman Lori Englebert named new Chief Commercial Officer Cash position of $228.6 million ...
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, a...
New research has determined that psilocybin may impact the brain. Psilocybin is the primary psychoactive compound found in hallucinogenic mushrooms. When ingested, it distorts an individual’s perception of time, among other changes. Researchers have observed that in animals, psilocyb...